Metoclox

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metoclox

Property Description
Active ingredient Metoclopramide
Primary Forms Tablet, Oral Solution, Injectable Solution
Pharmacological Class Prokinetic Agent and Antiemetic Agent
General Purpose Motility enhancement and Nausea control
Origin Synthetic (Substituted Benzamide)

Metoclox is a medication containing the single active substance Metoclopramide, which is typically formulated as the hydrochloride salt. This compound is classified as a synthetic organic substance derived from the antiarrhythmic drug procainamide. It is recognized as an essential medicine, reflecting its relevance in public health. Well-known brands such as Reglan and Maxolon share this same formulation, highlighting its broad recognition and utility.


The Classification of Metoclox: Prokinetic and Antiemetic

Metoclopramide is dually categorized as a prokinetic agent and an antiemetic agent. The antiemetic classification signifies its general purpose of controlling and preventing the symptoms of nausea and vomiting. As an antiemetic agent, it is utilized for its reliable action in clinical settings. This dual functionality distinguishes it from medications that only target stomach acid or only inhibit a single nausea pathway. Its combined functions serve to relieve symptoms stemming from sluggish digestion, such as persistent fullness, and the involuntary reflexes that cause sickness.


Available Forms and Core Composition

The active substance, Metoclopramide, is utilized in multiple pharmaceutical preparations, including the common tablet form for oral ingestion, an oral solution (liquid), and a sterile injectable solution. This range of dosage forms allows for administration via oral, intravenous (IV), and intramuscular (IM) routes. The availability of liquid and parenteral forms is a key feature, making it suitable for situations where a patient is unable to swallow tablets or requires immediate systemic action. As a single-ingredient product, Metoclopramide hydrochloride is the sole therapeutic agent, combined with basic excipients necessary to stabilize the final medicine.

Regulatory References

  1. World Health Organization’s List of Essential Medicines

What side effects are possible with Metoclox?

Possible Side Effects and Safety Information

The official safety profile of Metoclopramide (Metoclox) is classified by governmental regulatory documents, grouping potential adverse reactions by frequency and the body system affected. All statements reflect the high-level safety information documented in regulatory labeling, without providing clinical advice.


Frequency and System Classification

Adverse reactions are formally categorized into system-organ classes, including Nervous System Disorders, Gastrointestinal Disorders, Psychiatric Disorders, and Endocrine Disorders. Common reactions, reported in ge 1/100 patients, include drowsiness, restlessness (Akathisia), diarrhea, fatigue (asthenia), and headache. Less common effects, such as confusion and bradycardia, are also listed.


Serious Adverse Reactions

The official documents specify several serious adverse reactions, notably:

  • Tardive Dyskinesia (TD): This potentially irreversible disorder involves involuntary movements and is primarily associated with long-term use (generally over 12 weeks), a risk highlighted with a prominent regulatory warning.
  • Neuroleptic Malignant Syndrome (NMS): A rare but severe reaction that includes fever, muscle rigidity, and altered mental status.
  • Acute Extrapyramidal Symptoms (EPS): These reactions, such as dystonia and Parkinsonism, typically occur at the start of treatment or following a single administration.
  • Serious Cardiac Events: Circulatory collapse and severe bradycardia have been reported, particularly following rapid intravenous administration.

Population and Constraint Notes

The safety profile includes restrictions for specific patient groups and clinical conditions. Metoclox is contraindicated in children less than one year of age due to increased risk of neurological disorders and methemoglobinemia. Dose reduction is recommended for older adults and patients with moderate to severe renal or hepatic impairment. Use is prohibited in patients with conditions like GI hemorrhage, obstruction, or perforation, and in those with a history of pheochromocytoma or prior metoclopramide-induced TD.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Metoclox (Metoclopramide) is formally documented in regulatory prescribing information as primarily presenting with severe neurological and cardiovascular manifestations. These documented overdose presentations include signs of Central Nervous System (CNS) depression, such as somnolence, disorientation, and decreased level of consciousness, along with extrapyramidal reactions (e.g., involuntary movements and dystonia).

Life-threatening outcomes that have been officially reported include cardiovascular collapse, severe bradycardia, and potential cardiac or cardio-respiratory arrest. A rare, but documented, risk is methemoglobinemia, particularly in neonates.

Required Emergency Actions

The regulatory basis for management emphasizes that no specific antidote is known for Metoclopramide overdose; therefore, management is primarily symptomatic and supportive. Official guidance stipulates that emergency medical care is required immediately for any suspected overdose. This includes calling emergency services if the affected individual has collapsed, has a seizure, or is unresponsive. Intensive hospital monitoring of cardiovascular and respiratory function is necessary, and specific supportive treatments, such as intravenous anticholinergic agents, may be used to manage the extrapyramidal symptoms.

Therapeutic Uses of Metoclox

Main Uses and Benefits of Metoclox

Metoclox is a medication primarily used to manage specific gastrointestinal motility disorders and to prevent certain types of nausea and vomiting. It belongs to a class of drugs known as dopamine-receptor antagonists, which work by increasing the movements or contractions of the stomach and intestines.

Gastroesophageal Reflux Disease (GERD)

Metoclox is used for the short-term treatment of symptomatic gastroesophageal reflux. It is typically utilized when patients do not respond adequately to conventional treatments. The medication helps relieve symptoms such as heartburn and acid regurgitation by:

  • Increasing the resting tone of the lower esophageal sphincter, which helps prevent stomach acid from backing up into the esophagus.
  • Promoting faster emptying of food from the stomach into the small intestine.

Diabetic Gastroparesis

For individuals with diabetes, the nerves controlling the stomach muscles can become damaged, leading to a condition called gastroparesis (delayed gastric emptying). Metoclox is used to manage the symptoms associated with acute and recurrent diabetic gastroparesis, including:

  • Nausea and vomiting.
  • Early satiety (feeling full shortly after starting a meal).
  • Postprandial fullness and bloating.
  • Persistent anorexia.

By stimulating gastric motility, the medication assists in moving food through the digestive tract more efficiently, which can also aid in more predictable glucose absorption.

Prevention of Nausea and Vomiting

Metoclox is frequently utilized in clinical settings to prevent nausea and vomiting associated with various triggers. Its primary applications in this area include:

  • Chemotherapy-Induced Emesis: It helps manage the nausea and vomiting that can occur during or after cancer chemotherapy treatments.
  • Postoperative Nausea and Vomiting: It is used to prevent or treat nausea and vomiting that may occur following surgical procedures and anesthesia.

Facilitation of Medical Procedures

In certain diagnostic or medical procedures, Metoclox is used to assist healthcare providers by stimulating gastric emptying and intestinal transit. This is particularly useful during:

  • Small Bowel Intubation: Helping to pass a tube through the stomach and into the small intestine when the procedure is delayed by slow gastric emptying.
  • Radiological Examinations: Aiding the transit of barium through the digestive tract to allow for clearer imaging of the stomach and small intestine.

Regulatory References

  1. NIH DailyMed official drug label

Eligibility and Restrictions for Use

Official Eligibility Rules for Metoclox (Metoclopramide)

Official regulatory documents strictly define which populations are eligible to use Metoclox. Use is permitted for adults and for pediatric patients (age 1-18 years) for restricted, second-line indications like post-operative or chemotherapy-induced nausea and vomiting. Use in infants less than 1 year of age is contraindicated due to an increased risk of extrapyramidal disorders.


Absolute Contraindications

Metoclox must not be used by patients with certain pre-existing conditions as defined in the regulatory label:

  • Gastrointestinal hemorrhage, mechanical obstruction, or perforation.
  • Pheochromocytoma (risk of hypertensive crisis).
  • A history of Tardive Dyskinesia or seizure disorders (Epilepsy).

Restricted and Conditional Use

  • Organ Function: A dose reduction is formally required for patients with severe renal impairment or severe hepatic impairment.
  • Pregnancy/Lactation: While the medicine can be used if clinically needed during pregnancy, it is avoided at the end of pregnancy and not recommended during breastfeeding.
  • Older Adults (Geriatric): Use requires special consideration, often necessitating a lower starting dosage due to increased sensitivity to adverse effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metoclox interacts with several categories of other medicines, which may require avoiding co-administration or changing the dose of Metoclox or the other medicine. These interactions are officially documented based on their potential for altered medicine effects or increased risk of side effects.

Medicine Category Interaction Outcome & Constraint
Medicines affecting the brain and nerves (e.g., Antipsychotics, CNS depressants including alcohol, certain sedatives) Increased risk of serious adverse effects, including problems with movement or excessive drowsiness. Concomitant use must often be avoided.
Dopamine-related medicines (e.g., Levodopa) Metoclox may counteract the effects of these medicines. Co-administration should be avoided.
Enzyme-inhibiting medicines (e.g., strong inhibitors of CYP enzymes) These medicines slow the clearance of Metoclox from the body, increasing its concentration. Metoclox dosage reduction is typically required.
Medicines absorbed in the stomach (e.g., Digoxin) Metoclox alters how quickly food and medicines move through the stomach, which may change how the body absorbs these drugs. Monitoring for altered effects may be necessary.

Official regulatory information requires healthcare providers to assess these combinations before starting Metoclox treatment. Dosage adjustments or alternative treatments are necessary to manage the risk of serious interaction outcomes.

Mechanism of Action

Metoclox (Metoclopramide) exerts its physiological effects through two distinct mechanistic domains: central inhibition of reflex signaling and peripheral modulation of digestive tract muscle function.

Central Inhibition of Reflex Signaling

This mechanism involves the antagonism of dopamine D2 and serotonin 5-HT3 receptors within the brain's Chemoreceptor Trigger Zone (CTZ). By blocking these key receptors, the molecule restricts the transmission of humoral (blood-borne) chemical signals to the vomiting center, resulting in the inhibition of the signal transmission to the medullary vomiting center.

Peripheral Enhancement of Digestive Tract Motility

Metoclopramide acts on the Enteric Nervous System (ENS) by combining 5-HT4 receptor agonism with presynaptic D2 receptor antagonism. This dual action potentiates the release of Acetylcholine (ACh), resulting in increasing the amplitude and coordination of upper gastrointestinal tract smooth muscle contraction, increasing the rate of gastric emptying and small intestinal transit, and increasing the pressure of the Lower Esophageal Sphincter (LES). The effects on motility are largely confined to the upper GI tract, with minimal action on the colon. Furthermore, the D2 receptor antagonism also engages motor control pathways in the brain, which is a molecular consequence affecting motor control pathways.

Dosage and Administration Information

Metoclox (metoclopramide) is administered via the oral route (tablet, solution, or orally disintegrating tablet) or the parenteral route (intravenous or intramuscular injection). The instructions define the required dosage, administration timing, and duration constraints.

Official Administration Instructions

Parameter Oral Administration Parameters
Standard Single Dose 10 mg (adults), repeated up to three or four times daily.
Timing Constraint Must be administered 30 minutes before each meal and at bedtime.
Minimal Interval A 6 hour minimal interval must be respected between subsequent administrations of immediate-release forms.
Maximum Daily Dose Restricted to 30 mg or 0.5 mg/kg body weight, or up to 60 mg depending on the indication.

Duration and Adjustment Rules

Treatment duration is subject to established limits: it should not exceed a maximum of 5 days for acute nausea and vomiting or 12 weeks for chronic, approved conditions like Diabetic Gastroparesis. No use beyond these maximums is recommended or approved.

Dose Adjustment for Specific Populations:

Standard protocols involve dose reduction for patients with impaired organ function. For patients with moderate to severe renal or hepatic impairment, the daily dose must be reduced, typically by 50% to 75%. A lower starting dosage is also recommended for older adults.

Parenteral Administration:

Intravenous doses must be administered slowly over at least 1 to 3 minutes. For doses higher than 10 mg, the injectable solution may require dilution in 50 mL of a compatible parenteral solution (e.g., normal saline).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Metoclox

Evidence for Use in Managing Symptoms of Diabetic Gastroparesis

Short-term randomized controlled trials (RCTs) was evaluated in contexts involving fluctuating or unstable symptoms, typically comparing Metoclox against an inactive substance (placebo). These studies included adult populations diagnosed with diabetes and documented symptoms of delayed stomach emptying. Research examined outcomes related to physical discomfort by assessing how these symptoms change over time, using patient-reported outcomes describing perceived discomfort.

Findings describe patterns observed in these studies where patient-reported outcomes were monitored during the study period. However, research highlights that findings were mixed or inconsistent when comparing these patient-reported outcomes with objective measurements of how fast the stomach actually emptied. What remains uncertain is the long-term observation of the medicine, as long-term effects are not fully established. Data for sustained relief or use beyond approximately 12 weeks remain insufficient. This means that follow-up durations were limited, and data for extended outcomes remain insufficient.

Evidence for Controlling Acute and Delayed Nausea and Vomiting

The medicine was studied for its use in managing symptoms of nausea and vomiting in several acute settings. A significant body of evidence was applied in studies examining patient-reported experiences related to chemotherapy (CINV). Here, studies monitored outcomes related to the control of both immediate and delayed symptoms. Trials reported measurements related to the control of delayed nausea and vomiting, and evidence describes consistent patterns of measured outcomes in this specific research setting.

Metoclox was also evaluated in controlled trials related to post-operative nausea and vomiting (PONV). This research, typically involving a single, acute dose, examined outcomes related to preventing the incidence and severity of these episodes. The data structure for single-dose use is broad, but findings were mixed across different patient subgroups and dose comparisons. Research continues to explore combination treatments, and comparative data for the medicine’s use against newer antiemetic agents is limited.

Key Studies & References Metoclopramide in the treatment of diabetic gastroparesis (Systematic Review)

Frequently Asked Questions (FAQ)

Common questions about Metoclox (FAQ)


Q: How long does the effect of Metoclox last in the body?

Official pharmacological information indicates that the active ingredient, metoclopramide, has an elimination half-life of approximately 6 hours in healthy adults. The direct anti-nausea effects of a single dose are typically described as lasting for 1 to 2 hours after administration.


Q: Can Metoclox be taken with common over-the-counter cold medicines?

Regulatory information indicates that Metoclox may interact with other central nervous system (CNS) depressants, which includes some common ingredients found in cold medicines, particularly those that cause drowsiness. Combining Metoclox with these types of medicines may increase the risk of side effects like excessive drowsiness or confusion. Official regulatory documents indicate that concurrent use of all medicines should be discussed with a healthcare provider.


Q: Does Metoclox interact with caffeine or energy drinks?

Official regulatory documents do not specifically list common stimulants like caffeine as a formal drug interaction with Metoclox. However, the medicine may interact with substances that affect the central nervous system. Patients are typically advised to discuss all dietary intake, including highly caffeinated products, with a healthcare provider.


Q: Are there any foods or supplements that should be avoided while taking Metoclox?

Metoclox is officially instructed to be taken 30 minutes before meals, which is a timing constraint related to food. While specific common foods are not listed as being avoided, alcohol is a strictly known interacting substance that increases sedative side effects. Its effects on stomach emptying can also change how other oral medications and supplements are absorbed.


Q: How long do the side effects of Metoclox usually last?

The duration of side effects can vary depending on the type of reaction. Some acute neurological effects, such as Extrapyramidal Symptoms (EPS), often occur shortly after starting treatment and are often described as reversible. In contrast, Tardive Dyskinesia (TD) is a serious risk associated with long-term use and may not resolve completely, even after discontinuation.


Q: Are there any long-term effects described in studies of Metoclox use?

The most significant long-term risk described in regulatory warnings is Tardive Dyskinesia (TD), which involves involuntary, often irreversible movements. The duration of use is often restricted, typically to a maximum of 12 weeks for chronic conditions, due to the increased risk of TD associated with longer treatment periods.


Q: Can Metoclox make existing conditions, like kidney issues, worse?

Official documents note that Metoclox is mainly cleared from the body by the kidneys and liver. For patients who already have moderate to severe kidney or liver impairment, official guidelines recommend a reduced dose to prevent the drug from building up in the body and increasing the risk of adverse reactions. The medicine is also contraindicated (prohibited) for use with conditions like GI perforation or obstruction, which could be worsened by its action on the digestive tract.


Q: What kind of monitoring might be required while taking Metoclox?

Monitoring is necessary for patients with pre-existing conditions, particularly those with kidney, liver, or heart issues. Monitoring for fluid retention and changes in blood sugar is often needed for patients with related conditions. All patients are generally monitored for signs of neurological side effects, such as those related to Tardive Dyskinesia, throughout the course of treatment.


Q: Is Metoclox a type of painkiller?

Metoclox is classified by regulatory bodies primarily as a prokinetic agent and an antiemetic agent. This means it helps with stomach/intestinal movement and controls symptoms of nausea and vomiting. It is not classified as an analgesic, which is the class for traditional painkillers.


Q: How quickly does Metoclox typically start working?

The speed of action depends on the form of administration. For intravenous (IV) administration, the effects are described as rapid, generally starting within 1 to 3 minutes. After taking an oral dose, the concentration of the medicine typically reaches its peak in the bloodstream within about 1 to 2 hours.


Q: What happens if I miss a dose of Metoclox?

Official guidance states the next scheduled dose should be taken as planned. The next dose should then be taken at the regularly scheduled time. Official regulatory information specifies that taking extra medicine to compensate for a missed dose is not recommended.


Q: Can Metoclox cause drowsiness or affect my concentration?

Yes, drowsiness and fatigue (tiredness) are listed as common side effects of Metoclox in official adverse reaction profiles. Other effects such as confusion and dizziness are also possible, which can affect a person's mental alertness and concentration.


Q: Is it true that Metoclox can affect my sleep pattern?

Official safety information lists both drowsiness and fatigue as common side effects. Additionally, insomnia (difficulty sleeping) is included in the possible adverse reactions noted in consumer documents for Metoclox.


Q: What if I already take a vitamin supplement; does that interact with Metoclox?

The prokinetic action of Metoclox can change the absorption rate of many substances taken by mouth, including supplements. Regulatory documents indicate that patients are generally expected to inform their healthcare provider about all supplements, vitamins, and herbal products they are taking, as these can affect how Metoclox works or increase the risk of side effects.


Q: Are there non-drug ingredients in Metoclox that people should be aware of?

Yes. Official documentation emphasizes that the full list of ingredients should be reviewed to check for known allergies to any component. For example, the injectable form is noted to contain sulfite preservatives, which can pose a risk to susceptible individuals, such as those with asthma.


Q: How is Metoclox metabolized or removed from the body?

The active substance in Metoclox is primarily metabolized (broken down) by the liver. The resulting compounds are then largely eliminated from the body through the kidneys. Approximately 85% of an oral dose is typically recovered in the urine.


Q: Is there a generic version of Metoclox available?

Yes. The active ingredient in Metoclox is metoclopramide, which is the generic name. This generic formulation is widely available through various manufacturers, alongside well-known brand names such as Reglan and Maxolon.


Q: Can Metoclox affect the results of routine lab tests?

Official information indicates that Metoclox can cause an increase in the hormone prolactin, which might affect the results of certain lab tests. It can also cause a temporary rise in plasma aldosterone, a hormone related to the body's fluid balance.


Q: Why do some people report feeling nervous after taking Metoclox?

Restlessness, medically known as Akathisia, is a common side effect of Metoclox listed in official safety profiles. This is a condition of motor restlessness that is sometimes perceived by patients as internal anxiety or nervousness. In rare cases, severe anxiety has also been noted, especially after rapid intravenous administration.


Q: What information is available from the NIH about Metoclox?

The National Institutes of Health (NIH) provides two types of information. Its DailyMed resource contains the official regulatory drug label, including all warnings, indications, and side effects. The MedlinePlus site offers patient-focused information on the drug’s uses, how it is taken, and side effects in accessible language.


Q: Do studies suggest Metoclox is generally well-tolerated?

While studies confirm Metoclox's utility in certain short-term settings, regulatory documents highlight the potential for serious and potentially irreversible neurological side effects, notably Tardive Dyskinesia. This safety profile is why official limits restrict the duration of treatment, which is a key consideration when assessing overall tolerability.


Q: Does Metoclox carry a known risk of allergic reactions?

Yes. Hypersensitivity (a severe allergic reaction) to Metoclox or its components is an absolute contraindication for use. Official safety documents state that severe hypersensitivity reactions can occur, which may include symptoms like rash, hives, or swelling of the throat and face.


Q: Is Metoclox the same as other related drugs I've seen mentioned online?

Metoclox contains the single active substance, metoclopramide, classified as a dopamine receptor antagonist and prokinetic agent. Other drugs that treat similar symptoms, like nausea, often belong to different chemical or pharmacological classes. This means they operate via distinct mechanisms and may carry different safety profiles.


Q: What is known about the use of Metoclox while breastfeeding?

Official information indicates that Metoclox passes into breast milk in small amounts. While it is rarely associated with effects in the infant, regulatory bodies generally advise against its use during breastfeeding. Metoclox is generally restricted to short-term use in this context. Official guidance notes that alternative anti-sickness medicines may be preferred.


Q: Is it normal to feel a little dizzy after taking Metoclox?

Yes, dizziness is explicitly listed as a common or possible adverse effect in the official safety and consumer information documents for Metoclox.

How should Metoclox be stored and disposed of?

How to Store and Dispose of Metoclopramide

Metoclopramide must be stored according to regulatory requirements to maintain product stability. Oral dosage forms must be kept at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), and explicitly protected from freezing. Storage must be away from excessive heat and moisture.

The injectable solution is light sensitive and must be kept in its original outer carton until use. All forms must be stored out of the reach and sight of children.

For disposal, Metoclopramide is not on the list of medicines safe to flush. Unused or expired medication should be taken to a drug take-back location. If unavailable, mix the product with an undesirable substance, place it in a sealable container, and dispose of it in the household trash according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metoclox found in:

A-Z Index: